Canada Markets close in 6 hrs 28 mins

Pacific Biosciences of California, Inc. (PACB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.23+0.01 (+0.13%)
As of 09:31AM EDT. Market open.
Sign in to post a message.
  • T
    Tambo210
    On May 14, 2022, Peter Fromen, the Chief Commercial Officer of Pacific Biosciences of California, Inc. (the “Company”), notified the Company of his
    intention to resign, effective as of May 20, 2022, to pursue new opportunities. Mr. Fromen’s decision to resign did not result from any disagreement with
    the Company on any matter relating to the Company’s operations, policies or practices.
    The Company is conducting a search for its next Chief Commercial Officer. Until a successor is appointed, Christian Henry, Chief Executive Officer and
    President, will take over the Company’s marketing responsibilities, and Chris Seipert, Vice President, Customer Experience, and formerly the Company’s
    Vice President & General Manager – The Americas & EMEA, will take over the Company’s sales, service and support responsibilities.
  • R
    RV
    https://www.pacb.com/blog/hifi-sequencing-for-aav-gene-therapy/
    HiFi sequencing for AAV gene therapy: from discovery and design to production
  • R
    RV
    PACB and TWST:
    • Mainly owned by Real Money accounts e.g. Vanguard, BlackRock, State Street, Fidelity, Capital Group, Jackson Square Partners, etc.

    = nothing much to analyze as they are passive

    • Ark + Sumitomo + Nikko bloc + Casdin also in
  • R
    RV
    DECHENG CAPITAL MANAGEMENT III (CAYMAN), LLC 1,463,872 $13,321,000 4.08 8 1,463,872 0.6618% 13F 2022-03-31 2022-05-10 Q1 2022 9.10
  • R
    RV
    Folks: Infinity from ILMN vs PACB- all know a lot about sequencing:

    Albert Vilella
    @AlbertVilella
    The reply from $PACB PacBio on the Infinity Reads dataset that $ILMN Illumina produced in the form a series of IGV screenshots: https://pacb.com/blog/the-hifi-difference-getting-the-right-answer/ Thanks
    @sbarnettARK
    for pointing out

    https://twitter.com/AlbertVilella/status/1525114507508469765/photo/1

    Replying to
    @AlbertVilella
    Isn’t calling/phasing of HET SNVs in low complexity regions one way that Hifiasm is able to achieve such long phase blocks?

    Phillip A Richmond
    @Phil_A_Richmond
    Replying to
    @AlbertVilella
    and
    @sbarnettARK
    Spot on.

    The best part is that these are the cherrypicked infinity examples...curious to see a short tandem repeat expansion compared with two technologies...
    11:05 AM · May 13, 2022·Twitter for iPhone
  • R
    RM
    OT: Cathy purchased over 4 million shares of DNA today across ARKK & ARKG.. Our COH sits on their board..
  • R
    RV
    NIKKO ASSET MANAGEMENT AMERICAS, INC. 14,021,205 $127,873,000 0.94 1.29 25 2,106,180 6.3392% 13F 2022-03-31 2022-05-06 Q3 2020 19.63
  • D
    Daniel
    Dear Pacb shorters of 2022 - be thankful for your gains and get lost
  • R
    RV
    “Far more money has been lost by investors preparing for corrections, or trying to anticipate corrections, than has been lost in corrections themselves.”
    — Peter Lynch
  • R
    RV
    Simon Barnett
    @sbarnettARK
    ·
    20h
    A fun fact:

    PacBio has tiny, physical microscopes embedded in its chips that watch DNA get synthesized in real-time.
    These microscopes are the tiniest that exist. The observation volume is ~20 zeptoliters (10^-21 liters).
    To put this in perspective on a macro scale.

    The ratio of a PacBio waveguide to a one-liter bottle of water is about the same as a one-liter bottle of water to the number of liters of water in ALL of the Earth's oceans.

    https://themeasureofthings.com/results.php?.
  • D
    Daniel
    Got to love this statement: PacBio is in a strong financial position, and based on our estimates, we intend to fund the company’s current development and commercialization plans using the cash and investments on our balance sheet until we reach positive operating cash flows - that’s a finger to the short positions!
  • T
    Tambo210
    First quarter results

    Revenue of $33.2 million, a 14% increase compared with $29.0 million in the prior year period.
    Delivered a record 50 Sequel II/IIe systems during the quarter compared to 41 Sequel II/IIe systems placed in the prior year quarter.
    Installed base of 424 Sequel II/IIe systems as of March 31, 2022, compared with 244 as of March 31, 2021.
    Instrument revenue of $15.6 million, compared with $14.9 million in the prior-year period.
    Consumables revenue of $12.7 million compared with $10.4 million in the prior-year period.
    Service and other revenue of $4.9 million compared with $3.7 million in the prior-year period.

    No need for cash raise
  • B
    Biomimetics
    So I read the txt of the CC... my take home message from CH: 'Our product continues to be the choice among those engaged in complex genomic discovery applications. For the overwhelming bulk of industrial DNA companies doing applied work, we are still too expensive. We recognize this and have the funds and are on schedule to solve this defining challenge to growth and profitability. WAIT UNTIL NEXT YEAR!!!'
  • R
    RV
    CRISPR VISION
    @CrisprVision
    ·
    NVTA trading at 2x sales and $500m less than it’s $1.4b acquisition of ArcherDX. This is a company growing at a almost 50% per year. How does this make any sense?
  • f
    fludy
    Looks like yesterday ARKK added about 400K shares and ARKG about 200K

    That might help account for afternoon price rise.
  • S
    Sir John T
    PACB—-loved at $50. Hated at $7.
    Indicative of the backward and typically wrong thinking of most “investors.”
    You can buy 7+ times the PACB shares you could have acquired at the relatively recent high when the likes of Cathie Wood and her “exponential growth” theory drove this stock to it’s likely fair value 5 years in the future.
    Bios of all sorts are dead in the water but biotechnology remains alive and well. When the sector again becomes in vogue, we’ll look back at today’s price(s) and kick ourselves for not having the courage to have bought when opportunity stared us in the face.
  • D
    Daniel
    Institutional holdings increased to 96.7%!! Retail getting shaken out as usual. Have to admit, 2022 has been brutal for pacb stockprice. Below pre-pandemic levels now. HOWEVER, fundamentals and business transformed in last 24 months. BUY BUY BUY
  • R
    RV
    JACKSON SQUARE PARTNERS, LLC 22,542,589 $205,137,000 2.04 2.49 13 8,039,420 10.1919% 13F 2022-03-31 2022-05-13 Q4 2020 20.69
  • R
    RV
    CITADEL ADVISORS LLC 2,248,249 $20,460,000 0.00 0.00 1958 1,893,895 1.0165% 13F 2022-03-31 2022-05-16 Q3 2015 12.25